<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112632</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000430499</org_study_id>
    <secondary_id>KRDI-TUM-GIST-CST1571-BDE43</secondary_id>
    <secondary_id>EU-20507</secondary_id>
    <nct_id>NCT00112632</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor</brief_title>
  <official_title>Open-Label Trial of Neoadjuvant Imatinib Mesylate (Glivec) in Patients With Locally Advanced Malignant Gastrointestinal Stromal Tumors (GIST) Expressing c-Kit or Platelet-Derived Growth Factor Receptor-alpha</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. Giving imatinib mesylate before surgery may shrink the tumor&#xD;
      so that it can be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating&#xD;
      patients with locally advanced gastrointestinal stromal tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine radiographic objective response rates in patients with locally advanced&#xD;
           gastrointestinal stromal tumor treated with neoadjuvant imatinib mesylate.&#xD;
&#xD;
        -  Determine histological response in patients treated with this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine R0-resectability and organ-preserving resectability in these patients after&#xD;
           treatment with this drug.&#xD;
&#xD;
        -  Correlate radiographic imaging and metabolic imaging with histological response in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral imatinib mesylate once or twice daily for 4-6 months in the absence of&#xD;
      disease progression or unacceptable toxicity. Within 2-3 weeks after completion of imatinib&#xD;
      mesylate, patients with responding or stable disease undergo surgical resection.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks, 6 months, and then at&#xD;
      1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall tumor response (complete response, partial response, stable disease, and progression of disease)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression of disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed gastrointestinal stromal tumor&#xD;
&#xD;
               -  Locally advanced disease&#xD;
&#xD;
               -  Potentially resectable disease*&#xD;
&#xD;
                    -  No tumor that can be completely resected (R0) with sufficient margins NOTE:&#xD;
                       *Multivisceral resection may be necessary&#xD;
&#xD;
          -  Tumor must stain positive for c-Kit (CD117) or platelet-derived growth factor&#xD;
             receptor-alpha (PDGFRA) by immunohistochemistry&#xD;
&#xD;
          -  At least 1 site of measurable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limits of normal (ULN) (5 times ULN if hepatic&#xD;
             metastases are present)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  No chronic active hepatitis&#xD;
&#xD;
          -  No cirrhosis&#xD;
&#xD;
          -  No other chronic liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  No chronic renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III-IV cardiac disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Immunology&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  Must be medically fit to undergo surgery&#xD;
&#xD;
          -  No other primary malignancy within the past 5 years except basal cell skin cancer,&#xD;
             carcinoma in situ of the cervix, or a primary malignancy that is not currently&#xD;
             clinically significant and does not require active intervention&#xD;
&#xD;
          -  No gastrointestinal obstruction or major bleeding episode requiring immediate surgical&#xD;
             intervention&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No other severe or uncontrolled medical disease&#xD;
&#xD;
          -  No significant history of noncompliance to medical regimens&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent anticancer biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin)&#xD;
             unless disease is rapidly progressing&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic corticosteroid therapy unless approved by the study sponsor&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery except tumor biopsy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs unless disease is rapidly&#xD;
             progressing&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent warfarin for therapeutic anticoagulation&#xD;
&#xD;
               -  Concurrent low molecular weight heparin (e.g., enoxaparin sodium) or heparin for&#xD;
                  therapeutic anticoagulation allowed&#xD;
&#xD;
               -  Concurrent mini-dose warfarin (e.g.,1 mg/day) for prophylaxis of central venous&#xD;
                  catheter thrombosis allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Licht, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Comprehensive Cancer Center - Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik I at the University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <keyword>gastrointestinal stromal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

